These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21934185)

  • 1. [The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence].
    Pietrzak B; Dunaj A; Piątkowska K
    Postepy Hig Med Dosw (Online); 2011 Sep; 65():606-15. PubMed ID: 21934185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of the endocannabinoid system in the development of tolerance to alcohol.
    Basavarajappa BS; Hungund BL
    Alcohol Alcohol; 2005; 40(1):15-24. PubMed ID: 15550443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.
    Colombo G; Orrù A; Lai P; Cabras C; Maccioni P; Rubio M; Gessa GL; Carai MA
    Mol Neurobiol; 2007 Aug; 36(1):102-12. PubMed ID: 17952655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
    Maccioni P; Colombo G; Carai MA
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):55-9. PubMed ID: 20201816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
    Le Foll B; Forget B; Aubin HJ; Goldberg SR
    Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
    Sulcová A
    Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development. Drugs inspired by a drug.
    Marx J
    Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309
    [No Abstract]   [Full Text] [Related]  

  • 10. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
    Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
    J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system.
    Perra S; Pillolla G; Luchicchi A; Pistis M
    Alcohol Clin Exp Res; 2008 Mar; 32(3):443-9. PubMed ID: 18215217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895
    [No Abstract]   [Full Text] [Related]  

  • 14. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.
    Manzanares J; Ortiz S; Oliva JM; Pérez-Rial S; Palomo T
    Alcohol Alcohol; 2005; 40(1):25-34. PubMed ID: 15550451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry.
    McCulloch M; Zhou X; Xu Y; Brunell S; Spear L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 863(2):258-65. PubMed ID: 18258497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system: physiology and pharmacology.
    Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
    Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.